|
|
|
Insider
Information: |
Seidenberg Beth C |
Relationship: |
|
City: |
|
State: |
|
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
11 |
|
Direct
Shares |
320,491 |
|
Indirect Shares
|
23,818,703 |
|
|
Direct
Value |
$5,542,525 |
|
|
Indirect Value
|
$61,686,288 |
|
|
Total
Shares |
24,139,194 |
|
|
Total
Value |
$67,228,813 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
3
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
3
|
0
|
|
|
|
Gain/Loss Ratio : |
-3.0
|
0.0
|
Percentage
Gain/Loss : |
-69.3%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Amgen Inc |
AMGN |
Sr VP, Dev & Chief Med... |
2004-12-31 |
15,343 |
2004-01-14 |
0 |
Premium* |
|
Biocryst Pharmaceuticals Inc |
BCRX |
Director |
2006-05-03 |
0 |
2006-05-03 |
3,000 |
Premium* |
|
Tesaro, Inc. |
TSRO |
Director |
2019-01-22 |
0 |
2019-01-22 |
0 |
Premium* |
|
Epizyme, Inc. |
EPZM |
Director |
2019-06-30 |
8,481 |
2019-06-30 |
4,115,555 |
Premium* |
|
Atara Biotherapeutics, Inc. |
ATRA |
|
2023-05-31 |
115,689 |
2023-05-31 |
1,877,044 |
Premium* |
|
Armo Biosciences Inc |
ARMO |
Director |
2018-01-30 |
0 |
2018-06-22 |
0 |
Premium* |
|
Progyny, Inc. |
PGNY |
Director |
2023-06-23 |
36,210 |
2023-06-23 |
5,302,521 |
Premium* |
|
Vera Therapeutics, Inc. |
VERA |
Director |
2021-05-18 |
0 |
2023-03-28 |
1,946,995 |
Premium* |
|
Acelyrin, Inc. |
SLRN |
Director, 10% Owner |
2023-05-09 |
60,000 |
2023-05-09 |
9,790,729 |
Premium* |
|
Sagimet Biosciences Inc. |
SGMT |
Director |
2023-07-18 |
84,768 |
2023-07-18 |
46,875 |
Premium* |
|
Kyverna Therapeutics |
KYTX |
|
2024-02-12 |
0 |
2024-02-12 |
735,984 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
TSRO |
Tesaro, Inc. |
Director |
|
2019-01-22 |
4 |
D |
$75.00 |
$163,219,275 |
I/I |
(2,176,257) |
0 |
0 |
- |
|
TSRO |
Tesaro, Inc. |
Director |
|
2019-01-22 |
4 |
D |
$75.00 |
$3,443,025 |
D/D |
(45,907) |
0 |
0 |
- |
|
AMGN |
Amgen Inc |
Sr VP, Dev & Chief Medical Ofc |
|
2004-12-31 |
4 |
D |
$64.15 |
$392,662 |
D/D |
(6,121) |
20,720 |
|
- |
|
AMGN |
Amgen Inc |
Sr VP, Dev & Chief Medical Ofc |
|
2004-01-14 |
4 |
D |
$64.05 |
$119,005 |
D/D |
(1,858) |
26,335 |
|
- |
|
PGNY |
Progyny, Inc. |
Director |
|
2021-04-15 |
4 |
S |
$50.32 |
$912,151 |
I/I |
(18,127) |
8,805,015 |
0 |
- |
|
ARMO |
Armo Biosciences Inc |
Director |
|
2018-06-22 |
4 |
D |
$50.00 |
$213,334,150 |
I/I |
(4,266,683) |
0 |
0 |
- |
|
PGNY |
Progyny, Inc. |
Director |
|
2020-12-14 |
4 |
AS |
$42.00 |
$1,615,362 |
I/I |
(38,461) |
0 |
0 |
- |
|
PGNY |
Progyny, Inc. |
Director |
|
2020-11-27 |
4 |
AS |
$36.00 |
$692,316 |
I/I |
(19,231) |
38,461 |
0 |
- |
|
TSRO |
Tesaro, Inc. |
Director |
|
2016-03-18 |
4 |
B |
$35.19 |
$49,999,993 |
I/I |
1,420,858 |
227,255 |
2.1 |
- |
|
PGNY |
Progyny, Inc. |
Director |
|
2020-08-11 |
4 |
AS |
$30.00 |
$576,930 |
I/I |
(19,231) |
57,692 |
0 |
- |
|
EPZM |
Epizyme, Inc. |
Director |
|
2014-02-10 |
4 |
S |
$27.64 |
$10,740,967 |
I/I |
(388,584) |
3,838,167 |
0 |
- |
|
SLRN |
Acelyrin, Inc. |
Director |
|
2023-05-09 |
4 |
B |
$18.00 |
$22,500,000 |
I/I |
1,250,000 |
9,790,729 |
2.25 |
% |
|
SLRN |
Acelyrin, Inc. |
Director |
|
2023-05-09 |
4 |
B |
$18.00 |
$1,080,000 |
D/D |
60,000 |
60,000 |
3.92 |
% |
|
SGMT |
Sagimet Biosciences Inc. |
Director |
|
2023-07-18 |
4 |
B |
$16.00 |
$750,000 |
I/I |
46,875 |
46,875 |
2.1 |
% |
|
BCRX |
Biocryst Pharmaceuticals ... |
Director |
|
2006-05-03 |
4 |
B |
$15.21 |
$46,030 |
I/I |
3,000 |
3,000 |
2.1 |
- |
|
EPZM |
Epizyme, Inc. |
Director |
|
2018-07-02 |
4 |
A |
$13.55 |
$43,997 |
D/D |
3,247 |
6,447 |
0 |
- |
|
TSRO |
Tesaro, Inc. |
Director |
|
2012-07-03 |
4 |
B |
$13.50 |
$2,999,997 |
I/I |
222,222 |
171,028 |
2.1 |
- |
|
PGNY |
Progyny, Inc. |
Director |
|
2019-10-29 |
4 |
B |
$13.00 |
$999,999 |
I/I |
76,923 |
76,923 |
2.1 |
- |
|
EPZM |
Epizyme, Inc. |
Director |
|
2019-06-30 |
4 |
A |
$12.55 |
$12,676 |
D/D |
1,010 |
8,481 |
0 |
- |
|
EPZM |
Epizyme, Inc. |
Director |
|
2019-03-31 |
4 |
A |
$12.39 |
$12,687 |
D/D |
1,024 |
7,471 |
0 |
- |
|
EPZM |
Epizyme, Inc. |
Director |
|
2016-07-01 |
4 |
A |
$10.33 |
$33,056 |
D/D |
3,200 |
3,200 |
0 |
- |
|
VERA |
Vera Therapeutics, Inc. |
Director |
|
2023-02-09 |
4 |
B |
$7.25 |
$2,900 |
I/I |
400 |
1,654,630 |
2.1 |
- |
|
VERA |
Vera Therapeutics, Inc. |
Director |
|
2023-03-01 |
4 |
B |
$7.25 |
$725 |
I/I |
100 |
1,665,002 |
2.02 |
- |
|
VERA |
Vera Therapeutics, Inc. |
Director |
|
2023-03-03 |
4 |
B |
$7.25 |
$7,245 |
I/I |
1,000 |
1,689,380 |
2.1 |
- |
|
VERA |
Vera Therapeutics, Inc. |
Director |
|
2023-02-03 |
4 |
B |
$7.24 |
$334,220 |
I/I |
46,163 |
1,389,315 |
2.1 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|